Stanford Study Identifies Statins and Alpha Blockers as Potential Life-Extending Treatments for ALS Patients
Key Insights
Stanford University researchers analyzed medical records of 11,003 American veterans with ALS between 2009-2019, identifying 18 medications associated with prolonged survival in the largest drug repurposing study for the disease.
Statins (search) used for cholesterol management and alpha blockers (search) prescribed for enlarged prostates emerged as promising candidates that could extend survival in ALS patients, who typically live only three to five years after diagnosis.
The findings, published in Lancet Digital Health, represent the first electronic health record-based study to identify new ALS treatment candidates, though formal placebo-controlled trials are needed to confirm therapeutic benefits.
Stanford University researchers have identified potential new treatments for amyotrophic lateral sclerosis (search) (ALS) through the largest drug repurposing study conducted for the devastating neurodegenerative disease. The study, published in Lancet Digital Health, analyzed medical records of 11,003 American veterans diagnosed with ALS between 2009 and 2019, revealing that patients prescribed certain existing medications appeared to live longer than those who were not.
Major Findings from Electronic Health Records Analysis
The research team identified 18 medications taken for other medical conditions that were associated with prolonged survival in ALS patients. Among these, statins (search)—commonly prescribed cholesterol-lowering drugs—and alpha blockers (search), also known as alpha adrenergic receptor antagonists (search) used to improve urine flow in men with enlarged prostates, showed the most promising associations with extended survival.
"To our knowledge, this is the largest study to identify new ALS treatment candidates through drug repurposing and the first to be based on electronic health records," the authors wrote in their published findings.
Addressing Critical Unmet Medical Need
ALS, one of the main forms of motor neurone disease (search) (MND), causes progressive muscle weakness and can lead patients to lose the ability to walk as the condition worsens over time. The disease presents a significant clinical challenge, with patients typically surviving only three to five years after diagnosis and no cure currently available.
Lead author Professor Richard Reimer from Stanford University School of Medicine emphasized the urgent need for new therapeutic approaches. "Currently there are no truly effective treatments for ALS and people with the disease only live between three and five years after they have been diagnosed," Reimer stated. "Developing treatments for ALS has been difficult and disappointing because we don't understand the disease completely and it is difficult to study in the clinic."
Clinical Implications and Accessibility
The identified medications offer several advantages for potential therapeutic development. "Our findings suggest that treatment with statins (search) and alpha blockers (search) might prolong survival for individuals with ALS," Reimer explained. "Both statins and alpha blockers are generally well tolerated and available in inexpensive generic forms."
This accessibility factor could prove crucial for ALS patients, as the identified drugs are already widely available and have established safety profiles from their use in treating other conditions.
Future Research Directions
The research team outlined several critical questions that must be addressed before these findings can translate into clinical practice. "The next steps will be determining why these associations exist and who may benefit from the treatments," Reimer noted. "For example, are statins (search) affecting ALS survival by lowering cholesterol? Are they only helpful to individuals with elevated cholesterol?"
The researchers emphasized that formal placebo-controlled trials will be necessary to confirm the therapeutic benefits suggested by their observational study. "Once there is a better understanding of the link between these medications and survival for people with ALS, we hope that formal placebo controlled trials will confirm their benefit," Reimer added.
Significance for Drug Development
This study represents a novel approach to identifying potential ALS treatments by leveraging existing electronic health records rather than conducting traditional clinical trials from the outset. The methodology could accelerate the identification of therapeutic candidates for a disease where traditional drug development has faced significant challenges due to limited understanding of disease mechanisms and clinical study difficulties.